The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

Peking University

Status: Not yet enrolling

Conditions: CLL

Treatments: Drug: Zanubrutinib

Study type: Observational

Funder types: Other

Identifiers

NCT06489184

2024Zanu-RW-01

Details and patient eligibility

About

This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

Enrollment: 490 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Patients aged ≥18 years old
• 2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
• 3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib;
• 4.Prior or current use of Zanubrutinib for ≥3 months
• 5.At least one follow-up was recorded during Zanubrutinib treatment

Exclusion criteria